Teva (TEVA) EVP exercises RSUs and sells 17,295 ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported equity award activity and a share sale. On March 5, 2026, he exercised 17,295 restricted share units for 17,295 ordinary shares at no cost, as part of a previously granted award. The same day, he sold 17,295 ordinary shares in open-market transactions at a weighted average price of $31.6684, under a Rule 10b5-1 trading plan adopted on November 10, 2025, and in connection with the vesting of the units, including shares sold to cover tax withholding obligations. Following these transactions, he directly holds 85,755 ordinary shares and 51,887 restricted share units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Europe Commercial

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		17,295	A	(2)	103,050	D
Ordinary Shares(1)	03/05/2026		S(3)		17,295(4)	D	$31.6684(5)	85,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			17,295	(6)	(6)	Ordinary Shares(1)	17,295	$0	51,887	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 17,295 vested on March 5, 2026, 17,295 vesting on each of March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.

	/s/ Dov Bergwerl as attorney-in-fact for Richard Daniell	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Daniell Richard report at Teva (TEVA)?

Daniell Richard reported exercising 17,295 restricted share units into 17,295 ordinary shares, then selling 17,295 ordinary shares in open-market transactions. These actions were tied to a scheduled vesting event and executed under a pre-established Rule 10b5-1 trading plan.

How many Teva (TEVA) shares did Daniell Richard sell and at what price?

He sold 17,295 ordinary shares at a weighted average price of $31.6684. Footnotes state the sales occurred in multiple trades, with individual prices ranging from $31.26 to $32.34, and full trade details are available upon request from the reporting person.

What equity awards vested for Daniell Richard at Teva (TEVA)?

17,295 restricted share units vested for Daniell Richard on March 5, 2026. Each unit represents a right to receive one ordinary share or the cash value of one ordinary share, and this vesting is part of a multi-year grant schedule extending through March 5, 2029.

Were Daniell Richard’s Teva (TEVA) share sales under a 10b5-1 plan?

Yes. The filing notes the reported transaction was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans allow pre-arranged trading of shares, providing structure for insider transactions around equity award vesting events.

How many Teva (TEVA) shares and RSUs does Daniell Richard hold after these transactions?

After the reported activity, he directly owns 85,755 ordinary shares and 51,887 restricted share units. These positions reflect the conversion of vested units into shares and the subsequent sale of 17,295 shares associated with the same vesting event.

Why did Daniell Richard sell shares when his Teva (TEVA) RSUs vested?

Footnotes explain that all 17,295 vested shares were sold, including shares to cover tax withholding obligations tied to vesting. This indicates the sale was linked to managing tax liabilities arising from the RSU settlement, alongside execution of his 10b5-1 trading plan.